Free Trial

Becton, Dickinson and Company (BDX) Competitors

$226.80
-1.99 (-0.87%)
(As of 04:10 PM ET)

BDX vs. DXCM, RMD, BSX, BAX, SYK, WST, MCK, ZTS, MRNA, and EW

Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include DexCom (DXCM), ResMed (RMD), Boston Scientific (BSX), Baxter International (BAX), Stryker (SYK), West Pharmaceutical Services (WST), McKesson (MCK), Zoetis (ZTS), Moderna (MRNA), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector.

Becton, Dickinson and Company vs.

DexCom (NASDAQ:DXCM) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

DexCom has a net margin of 16.82% compared to DexCom's net margin of 6.76%. Becton, Dickinson and Company's return on equity of 31.01% beat DexCom's return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom16.82% 31.01% 10.29%
Becton, Dickinson and Company 6.76%13.90%6.73%

DexCom currently has a consensus target price of $141.67, suggesting a potential upside of 11.65%. Becton, Dickinson and Company has a consensus target price of $281.40, suggesting a potential upside of 23.73%. Given DexCom's higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.93
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

97.8% of DexCom shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

DexCom has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

DexCom received 362 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 71.92% of users gave DexCom an outperform vote while only 62.29% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
DexComOutperform Votes
950
71.92%
Underperform Votes
371
28.08%
Becton, Dickinson and CompanyOutperform Votes
588
62.29%
Underperform Votes
356
37.71%

Becton, Dickinson and Company has higher revenue and earnings than DexCom. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$3.62B13.86$541.50M$1.5581.43
Becton, Dickinson and Company$19.37B3.39$1.48B$4.5450.07

In the previous week, Becton, Dickinson and Company had 5 more articles in the media than DexCom. MarketBeat recorded 21 mentions for Becton, Dickinson and Company and 16 mentions for DexCom. Becton, Dickinson and Company's average media sentiment score of 1.06 beat DexCom's score of 0.53 indicating that DexCom is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
11 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DexCom beats Becton, Dickinson and Company on 13 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDX vs. The Competition

MetricBecton, Dickinson and CompanySurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$65.69B$3.89B$4.94B$17.72B
Dividend Yield1.66%1.79%2.80%3.53%
P/E Ratio50.079.54129.4022.62
Price / Sales3.3971.802,531.8310.26
Price / Cash11.3248.1532.6015.70
Price / Book2.564.224.955.10
Net Income$1.48B$4.68M$103.73M$974.28M
7 Day Performance-3.21%-1.30%-1.00%-1.14%
1 Month Performance-1.83%1.35%3.41%4.77%
1 Year Performance-5.73%17.31%5.15%23.90%

Becton, Dickinson and Company Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXCM
DexCom
4.9541 of 5 stars
$130.84
+0.1%
$141.67
+8.3%
+10.7%$52.03B$3.62B84.419,600Analyst Downgrade
Short Interest ↓
Positive News
RMD
ResMed
4.4096 of 5 stars
$218.28
-0.2%
$202.80
-7.1%
-1.0%$32.07B$4.22B33.5310,140
BSX
Boston Scientific
4.6323 of 5 stars
$75.69
+0.4%
$75.32
-0.5%
+48.1%$111.04B$14.24B63.6148,000Analyst Forecast
Short Interest ↓
BAX
Baxter International
4.9252 of 5 stars
$34.45
-1.6%
$45.73
+32.7%
-17.9%$17.56B$14.81B6.6360,000Short Interest ↓
Analyst Revision
SYK
Stryker
4.8346 of 5 stars
$330.51
+0.2%
$365.94
+10.7%
+23.1%$125.91B$20.50B37.7352,000
WST
West Pharmaceutical Services
4.9417 of 5 stars
$337.01
-1.7%
$435.20
+29.1%
-3.4%$24.55B$2.93B44.4610,600
MCK
McKesson
4.5577 of 5 stars
$552.38
-2.1%
$571.47
+3.5%
+44.5%$71.80B$308.95B24.6851,000
ZTS
Zoetis
4.7104 of 5 stars
$172.79
-0.9%
$211.75
+22.5%
+3.2%$78.84B$8.54B33.2914,100Dividend Announcement
Short Interest ↑
Analyst Revision
MRNA
Moderna
3.3762 of 5 stars
$143.69
+1.9%
$126.46
-12.0%
+32.0%$55.07B$6.85B-9.175,600Analyst Revision
Gap Down
EW
Edwards Lifesciences
4.7205 of 5 stars
$90.34
+0.6%
$93.88
+3.9%
+7.3%$54.44B$6.00B38.9419,800Short Interest ↓

Related Companies and Tools

This page (NYSE:BDX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners